A detailed history of Oracle Alpha Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Oracle Alpha Inc. holds 11,538 shares of NRIX stock, worth $228,798. This represents 0.3% of its overall portfolio holdings.

Number of Shares
11,538
Previous 17,434 33.82%
Holding current value
$228,798
Previous $180 Million 5.73%
% of portfolio
0.3%
Previous 0.23%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$7.77 - $15.66 $45,811 - $92,331
-5,896 Reduced 33.82%
11,538 $170 Million
Q4 2023

Feb 14, 2024

BUY
$4.25 - $10.71 $74,094 - $186,718
17,434 New
17,434 $180 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $935M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Oracle Alpha Inc. Portfolio

Follow Oracle Alpha Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oracle Alpha Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oracle Alpha Inc. with notifications on news.